![Figure 4. HMCL exhibit prosurvival stress responses following treatment with PKC412. (A) Treatment with PKC412 (5 μM) induces expression of HSP70 as measured by flow cytometry (⊡ indicates NCI-H929; ▪, LP-1; *P = .023 and .026, respectively, versus DMSO treatment). Graph represents data from 3 individual experiments. (B) Treatment with PKC412 (5 μM) induces expression of HSP90 as measured by flow cytometry (⊡ indicates NCI-H929; ▪, LP-1; *P = .020 and .027, respectively, versus DMSO treatment). Graph represents data from 3 individual experiments. (C) PKC412 treatment of the HMCL NCI-H929 induces NFκB activation as determined by p50/p65 nuclear translocation. Increased NFκB nuclear translocation is dose (1 μM versus 3 μM) and time (24 versus 72 hours) dependent (⊡ indicates NCI-H929; ▪, LP-1). Graph represents data from 3 individual experiments (bortezomib [B] was included as a negative control). (D) PKC412 (P) (5 μM) treatment induces transcriptional activation of NFκB as determined by luciferase assay (measured after 18 hours of treatment) (⊡ indicates NCI-H929). Graph represents data from 3 individual experiments). Error bars for all graphs indicate SEM.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/109/4/10.1182_blood-2006-05-014092/4/zh80040708260004.jpeg?Expires=1743078345&Signature=e~a52YLewk60N0QfdU9efzCDCOoC4Fg6ymaEmkQPUUN947wdpu4N31WTTRN3sW9VuGuvZeJuLBnftMByMqr9OuiEd6X1y8pZCEWcSmHmUpEzHZeauwsJZHbtybb9~1NvuwidDx6lEJXww1~dPJZxJIn0izhzmHe6pMjeGZPOjR5QQIiLY7kg0E~7ozRiXVlR7wo58uyMkgd~ZWQogSULyfV2wDODwGmiAWTix4MHUl-sawiVAc37V-BUqiWDmz7-am-Shsq7wZgg~ZIEUAp~vja3E7FjU9CRwnN~TEolH7NRa4Mp3QKsw4mTRkQvNWVa7R5MvgbO983MK3pnk3NhVQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
HMCL exhibit prosurvival stress responses following treatment with PKC412. (A) Treatment with PKC412 (5 μM) induces expression of HSP70 as measured by flow cytometry (⊡ indicates NCI-H929; ▪, LP-1; *P = .023 and .026, respectively, versus DMSO treatment). Graph represents data from 3 individual experiments. (B) Treatment with PKC412 (5 μM) induces expression of HSP90 as measured by flow cytometry (⊡ indicates NCI-H929; ▪, LP-1; *P = .020 and .027, respectively, versus DMSO treatment). Graph represents data from 3 individual experiments. (C) PKC412 treatment of the HMCL NCI-H929 induces NFκB activation as determined by p50/p65 nuclear translocation. Increased NFκB nuclear translocation is dose (1 μM versus 3 μM) and time (24 versus 72 hours) dependent (⊡ indicates NCI-H929; ▪, LP-1). Graph represents data from 3 individual experiments (bortezomib [B] was included as a negative control). (D) PKC412 (P) (5 μM) treatment induces transcriptional activation of NFκB as determined by luciferase assay (measured after 18 hours of treatment) (⊡ indicates NCI-H929). Graph represents data from 3 individual experiments). Error bars for all graphs indicate SEM.
